Praluent patent infringement, Sanofi and Regeneron to appeal

Sanofi and Regeneron Pharmaceuticals announced they will appeal the injunction granted today by the District Court for the District of Delaware, US; preventing the commercialization and manufacturing of Praluent in the US for having infringed two Amgen patents. The two companies believe Amgen’s claims are invalid and will also appeal a prior jury verdict favorable to Amgen. Praluent was the first product from the class of PCSK9 inhibitors to be approved in the US and to be available in two different doses. Its effect on cardiovascular morbidity and mortality has not yet been determined.
(Source Sanofi press release)